Our faculty comprises 10 schools, various centres and institutes, each with a unique purpose and focus. We are committed to making maximum impact through an ongoing pursuit of excellence and innovation.
Dr Kim Jacobson, lab head from the Monash Biomedicine Discovery Institute (BDI), has received the Bellberry-Viertel Fellowship for her work on epigenetic regulation of humoral immunity in health and disease.
A Monash University academic neurologist has joined forces with other global experts in multiple sclerosis (MS) research and treatment to create – for the first time – a consensus for measurable standards of MS care.
A study by critical care researchers has found that as the trauma cases drained from regional hospitals to The Alfred, Royal Children’s and Royal Melbourne hospitals, rural clinicians dealing with these patients have become ‘de-skilled’ and less confident in aspects related to care for injured patients.
Back pain is the world’s leading cause of disability, affecting half a billion people worldwide. While there are a variety of treatments available, effective therapies are limited. The use of antidepressants to treat back pain is rapidly increasing, with high doses prescribed for depression and lower doses for chronic pain. However, there is currently a lack of evidence for their effectiveness, particularly for the use of low-doses.